Immunogenicity of locally acting large molecule products: An overview.

Authors

Lei He, Ping Ji, Amit Golding, Yunzhao Ren, Chinmay Shukla, William Boyd, Rhea Lloyd, Chandrahas Sahajwalla

Published in

Journal of clinical pharmacology. Volume 66. Issue 9. Pages e70298.

Abstract

Locally acting large molecule drug products, including biologics, are designed for site-specific pharmacological action with minimal systemic exposure. Immunogenicity is generally assessed to the same extent in the clinical development programs for these locally acting large molecule drug products as for biological products given systemically. However, it is uncertain whether the local route of administration bears the same clinical immunogenicity concerns relative to systemic administration. This overview examines the immunogenic potential of locally acting large molecules, summarizing the anti-drug antibody incidence and its impact on pharmacokinetics, safety, and efficacy, and highlighting the specific immunogenicity risk profiles for these locally acting drugs and biologics.

PMID:
42775505
Bibliographic data and abstract were imported from PubMed on 23 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.